Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms

Toxicon

Volumn 76, Issue , 2013, Pages 63-76

  León, Guillermo ^a   Herrera, María ^a   Segura, Álvaro ^a   Villalta, Mauren ^a   Vargas, Mariángela ^a   Gutiérrez, José María ^a  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Adverse reactions; Anaphylactic reactions; Anaphylactoid reactions; Early reactions; Serum sickness; Snake antivenom

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; AUTOANTIBODY; CD16 ANTIGEN; CHLORPHENIRAMINE MALEATE; CIMETIDINE; DEXCHLORPHENIRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROMETHAZINE; PROPIOLACTONE; RANITIDINE; SNAKE VENOM ANTISERUM;

ADVERSE DRUG REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD PRESSURE; BRONCHOSPASM; CHILL; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; DRUG FATALITY; DRUG FORMULATION; ENVENOMATION; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; MYALGIA; NAUSEA; NOMENCLATURE; NONHUMAN; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; RESPIRATORY COLLAPSE; RESPIRATORY TRACT DISEASE; RIGOR; SHOCK; SIDE EFFECT; SMOOTH MUSCLE SPASM; SWEATING; TACHYCARDIA; URTICARIA; VASODILATATION; WORLD HEALTH ORGANIZATION;

ANIMALIA;

ADVERSE REACTIONS; ANAPHYLACTIC REACTIONS; ANAPHYLACTOID REACTIONS; EARLY REACTIONS; SERUM SICKNESS; SNAKE ANTIVENOM;

ADMINISTRATION, INTRAVENOUS; ANAPHYLAXIS; ANIMALS; ANTIVENINS; HUMANS; IMMUNITY, HUMORAL; SERUM SICKNESS; SNAKE BITES; SNAKE VENOMS;

EID: 84884925820     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.09.010     Document Type: Review

References (184)

1. Abubakar I.S., Abubakar S.B., Abdulrazaq G.H., Nasidi A., Durfa N., Yusuf P.O., Larnyang S., Garnvwa J., Sokomba E., Salako L., Theakston R.D.G., Juszczak E., Alder N., Warrell D.A., The Nigeria-UK EchiTab Study Group Randomized controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenomings in Nigeria. PLoS Negl. Trop. Dis. 2010, 4:e767.
2. Acconci C., Legallais C., Vijayalakshmi M., Alves S.M. Depyrogenation of snake antivenom serum solutions by hollow fiber-based pseudobioaffinity filtration. J. Membr. Sci. 2000, 173:235-245.
3. Amin M.R., Mamun S.M.H., Rashid R., Rahman M., Ghose A., Sharmin S., Rahman M.R., Faiz M.A. Anti-snake venom: use and adverse reaction in a snake bite study clinic in Bangladesh. J. Venom. Anim. Toxins Incl. Trop. Dis. 2008, 14:660-672.
4. Ariaratnam C.A., Sjostrom L., Raziek Z., Kularatne A.M., Arachichi R.W.K., Sheriff M.H.R., Theakston R.D.G., Warrell D.A. An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii). Trans. R. Soc. Trop. Med. Hyg. 2001, 95:74-80.
5. Atkinson J.P. The fractional precipitation of the globulin and albumin of normal horses serum and diphtheria antitoxic serum, and the anti-toxic strength of the precipitates. J. Exp. Med. 1900, 5:67-76.
6. Ayuso R., Lehrer S.B., López M., Reese G., Ibáñez M.D., Martín Esteban M., Ownby D.R., Schwartz H. Identification of bovine IgG as a major cross-reactive vertebrate meat allergen. Allergy 2000, 55:348-354.
7. Banks K.L., McGuire T.C. Surface receptors on neutrophils and monocytes from immunodeficient and normal horses. Immunology 1975, 28:581-588.
8. Barandun S., Kistler P., Jeunet F., Isliker H. Intravenous administration of human γ-globulin. Vox Sang. 1962, 7:157-174.
9. Baumann U., Chouchakova N., Gewecke B., Kõhl J., Carroll M.C., Schmidt R.E., Gessner J.E. Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. J. Immunol. 2001, 167:1022-1027.
10. Bentur Y., Raikhlin-Eisenkraft B., Galperin M. Evaluation of antivenom therapy in Vipera palaestinae bites. Toxicon 2004, 44:53-57.
11. Bernhisel-Broadbent J., Yolken R.H., Sampson H.A. Allergenicity of orally administered immunoglobulin preparations in food-allergic children. Pedriatrics 1991, 87:208-214.
12. Bordet J. Les leukocytes et les proprietes actives du serum chez les vaccines. Ann. Inst. Pasteur 1895, 9:462-506.
13. Brazil V. Contribução ao estudo do veneno ophidico. Rev. Médica São Paulo 1903, 6:265-278.
14. Brian M.J., Vince J.D. Treatment and outcome of venomous snake bite in children at Port Moresby General Hospital, Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 1987, 81:850-852.
15. Bucaretchi F., Douglas J.L., Fonseca M.R.C.C., Zmabrone F.A.D., Vieira R.J. Envenenamento ofídico em crianças: Frequència de reações precoces ao antiveneno em pacientes que receberam pré-tratamento com antagonistas H1 e H2 da histamina e hidrocortisona. Rev. Inst. Med. Trop. São Paulo 1994, 36:451-457.
16. Burnouf T., Griffiths E., Padilla A., Seddik S., Stephano M.A., Gutiérrez J.M. Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals 2004, 32:115-128.
17. Cahen Y.D., Fritsch R., Wüthrich B. Food allergy with monovalent sensitivity to poultry meat. Clin. Exp. Allergy 1998, 28:1026-1030.
18. Calmette A. Contribution à l'étude du venin des serpents. Immunisation des animaux et traitement de l'envenimation. Ann. l'Inst. Pasteur 1894, VIII:275-291.
19. Cannon R., Ruha A.M., Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom. Ann. Emerg. Med. 2008, 51:407-411.
20. Cardoso J.L.C., Fan H.W., Franca F.O.S., Jorge M.T., Leite R.P., Nishioka S.A., Avila A., Sano-Martins I.S., Tomy S.C., Santoro M.L., Chudzinski A.M., Castro S.C.B., Kamiguti A.S., Kelen E.M.A., Hirata M.H., Mirandola R.M.S., Theakston R.D.G., Warrell D.A. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil. Q. J. Med. 1993, 86:315-325.
21. Caron E.J., Manock S.R., Maudlin J., Koleski J., Theakston R.D.G., Warrell D.A., Smalligan R.D. Apparent marked reduction in early antivenom reactions compared to historical controls: was it prophylaxis or method of administration?. Toxicon 2009, 54:779-783.
22. Chippaux J.P., Goyffon M. Producers of antivenom sera. Toxicon 1983, 21:739-752.
23. Chippaux J.P., Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 1998, 36:823-846.
24. 2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans. R. Soc. Trop. Med. Hyg. 1998, 41:207-211. H 92, 657-662.
25. 2: results of a clinical trial in northern Cameroon. Am. J. Trop. Med. Hyg. 1999, 61:1017-1018.
26. 2 polyvalent equine antivenom for African snake bites in Benin. Am. J. Trop. Med. Hyg. 2007, 77:538-546.
27. Coombs R.R.A., Gell P.G.H. Classification of allergic reactions responsible for drug hypersensitivity reactions. Clinical Aspects of Immunology 1968, 575-596. Davis, Philadelphia. R.R.A. Coombs, P.G.H. Gell (Eds.).
28. Corrigan P., Russell F.E., Wainschel J. Clinical reactions to antivenin. Toxins: Animal, Plant and Microbial 1978, 457-465. Pergamon Press, Oxford. P. Rosenberg (Ed.).
29. Cupo P., Azevedo-Marques M.M., Menezes J.B., Hering S.E. Reações de hipersensibilidade imediatas após uso intravenoso de soros antivenenos: Valor prognóstico des testes de sensibilidade intradérmicos. Rev. Inst. Med. Trop. São Paulo 1991, 33:115-122.
30. Cupo P., Azevedo-Marques M.M., Sarti W., Hering S.E. Proposal of abolition of the skin sensitivity test before equine rabies immune globulin application. Rev. Inst. Med. Trop. São Paulo 2001, 43:51-53.
31. Dart R.C., Seifert S.A., Boyer L.V., Clark R.F., Hall E., McKinney P., McNelly J., Kitchens C.S., Curry S.C., Bogdan G.M., Ward S.B., Porter R.S. A randomized multicenter trial of crotaline polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch. Intern. Med. 2001, 161:2030-2036.
32. da Silva I.,M., Tavares A.M. Comparative evaluation of adverse effects in the use of powder trivalent antivenom and liquid antivenoms in Bothrops snake bites. Rev. Soc. Bras Med. Trop. 2012, 45:523-525.
33. de Andrade F.G., Eto S.F., Navarro A.C., Gonzales D.T., Vieira N.J., Cheirubim A.P., de Paula S., Venâncio E.J. The production and characterization of anti-bothropic and anti-crotalic IgY antibodies in laying hens: a long term experiment. Toxicon 2013, 66:18-24.
34. de Silva H., Pathmeswaran A., Ranasinha Ch., Jayamanne Sh., Samarakoon S., Hittharage A., Kalupahana R., Ratnatilaka G.A., Uluwatthage W., Aronson J.K., Armitage J.M., Lalloo D.G., de Silva J. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011, 8(5):e1000435. 10.1371/journal.pmed.1000435.
35. Descotes J., Choquet-Kastylevsky G. Gell and Coombs's classification: is it still valid?. Toxicology 2001, 158:43-49.
36. Després N., Grant A.M. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin. Chem. 1998, 44:440-454.
37. 2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. Toxicon 1989, 27:297-303.
38. Edelman G.M. Dissociation of γ globulin. J. Am. Chem. Soc. 1959, 81:3155.
39. European Agency for the Evaluation of Medicinal Products (EMEA) Note for Guidance on Production and Quality Control or Animal Immunoglobulins and Immunosera for Human Sue 2002, London, UK. http://www.emea.eu.int.
40. Erdei A., Tóth G.K., Andrásfalvy M., Matkó J., Bene L., Bajtay Z., Ischenko A., Rong X., Pecht I. Inhibition of IgE-mediated triggering of mast cells by complement-derived peptides interacting with the FceRI. Immunol. Lett. 1999, 68:79-82.
41. Erdei A., Andrásfalvy M., Péterfy H., Tóth G., Pecht I. Regulation of mast cell activation by complement-derived peptides. Immunol. Lett. 2004, 92:39-42.
42. Esteves M.B., Binaghi R.A. Antigenic similarities among mammalian immunoglobulin. Immunology 1972, 23:137-145.
43. Estrada R., Herrera M., Segura A., Araya J., Boschini C., Gutiérrez J.M., León G. Intravenous administration of equine derived antivenom did not induce anaphylactoid reactions in non envenomed horses and cows. Biologicals 2010, 38:664-669.
44. Eysink P.E.D., Bindels P.J.E., Stapel S.O., Bottema B.J.A.M., Van Der Zee J.S., Aalberse R.C. Do levels of immunoglobulin G antibodies to food predict the development of immunoglobulin E antibodies to cat, dog and/or mice?. Clin. Exp. Allergy 2002, 32:556-562.
45. Farrar H.C., Grayham T., Bolden B., Vyas D., Graham J., James L.P. The use and tolerability of Crotalidae Polyvalent Immune Fab (Ovine) in pediatric envenomations. Clin. Pediatr. (Phila.) 2012, 51:945-949.
46. Fernández G.P., Segura A., Herrera M., Velasco W., Solano G., Gutiérrez J.M., León G. Neutralization of Bothrops mattogrossensis snake venom from Bolivia: Experimental evaluation of llama and donkey antivenoms produced by caprylic acid precipitation. Toxicon 2010, 55:642-645.
47. Frommhagen L.H., Fudenberg H. The role of aggregated gamma-globulins in the anticomplementary activity of human and animal sera. J. Immunol. 1962, 89:336-343.
48. Fuentes M.M., Palacios R., Garcés M.M., Caballero M.L., Moneo I. Isolation and characterization of a heat-resistant beef allergen: myoglobin. Allergy 2004, 59:327-331.
49. García M., Monge M., León G., Lizano S., Segura E., Solano G., Rojas G., Gutiérrez J.M. Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation. Biologicals 2002, 30:143-151.
50. Gawarammana I.B., Kularatne S.A.M., Dissanayake W.P., Kumarasiri R.P.V., Senanayake N., Ariyasena H. Parallel infusion of hydrocortisone±chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. A randomized, double-blind, placebo-controlled study. Med. J. Aust. 2004, 180:20-23.
51. Gell P.G.H., Coombs R.R.A. The classification of allergic reactions underlying disease. Clinical Aspects of Immunology 1963, 317-337. Blackwell Science, Oxford. R.R.A. Coombs, P.G.H. Gell (Eds.).
52. Gibson R.B. The concentration of antitoxin for therapeutic use. J. Biol. Chem. 1906, 1:161-170.
53. 2 antivenoms. An example: new polyvalent European viper antivenom (equine). Envenomings and Their Treatments 1996, 161-172. Editions Fondation Marcel Merieux, Lyon. C. Bon, M. Goyffon (Eds.).
54. Grasset E., Christensen P.A. Enzyme-purification of polyvalent antivenene against southern and equatorial African colubrine and viperine venoms. Trans. R. Soc. Trop. Med. Hyg. 1947, 41:207-211.
55. Guidolin R., Morais J., Stephano M.A., Marcelino J.R., Yamaguchi I.K., Higashi H.G. Effect of β-propiolactone treatment on the complement activation mediated by equine antisera. Rev. Inst. Med. Trop. São Paulo 1997, 39:119-122.
56. Gutiérrez J.M. Snakebite envenoming: a public health perspective. Public Health-Methodology, Environmental and Systems Issues 2012, 131-162. InTech, Rojeka, Croatia. J. Madock (Ed.).
57. Gutiérrez J.M., León G., Lomonte B. Pharmacokinetic and pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin. Pharmacokinet. 2003, 42:721-741.
58. Gutiérrez J.M., León G., Lomonte B., Angulo Y. Antivenoms for the treatment of snakebite envenomings. Inflamm. Allergy Drug Targets 2011, 10:369-380.
59. Gutsmann T., Schrimm A.B., Brandenburg K. The physicochemistry of endotoxins in relation to bioactivity. Int. J. Med. Microbiol. 2007, 297:341-352.
60. Habib A.G. Effect of pre-medication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analysis. Drug Saf. 2011, 34:869-880.
61. Haro L., Lang J., Bedry R., Guelon D., Harry P., Marchal-Mazet F., Jouglard J., investigateurs de l' essai SVE Envenimations par vipers européennes. Étude multicentrique de tolerance de Viperfav™, nouvel antivenin par voie intraveineuse. Ann. Fr Anesth. Réanim 1998, 17:681-687.
62. Harrison R.A., Hasson S.S., Harmsen M., Laing G.D., Conrath K., Theakston R.D.G. Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon 2006, 47:364-368.
63. Helms Ch.M., Allen P.Z. Studies on equine immunoglobulins. II. Antigenic interrelationships among horse IgG, IgG(T) and antipneumococcal γ1 component. J. Immunol. 1970, 105:1253-1263.
64. Henning Ch., Rink L., Fagin U., Jabs W.J., Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J. Immunol. Methods 2000, 235:71-80.
65. Herrera M., León G., Segura A., Meneses F., Lomonte B., Chippaux J.P., Gutiérrez J.M. Factors associated with adverse reactions induced by whole IgG preparations: comparison between horse, sheep and camel IgGs. Toxicon 2005, 46:775-781.
66. Hitchcock P.J., Leive L., Mäkelä H., Rietschel E.T., Strittmatter W., Morrison D.C. Lipopolysaccharide nomenclature: past, present and future. J. Bacteriol. 1986, 166:699-705.
67. Hodgson J.C. Endotoxin and mammalian host response during experimental disease. J. Comp. Path 2006, 135:157-175.
68. Holstege C.P., Wu J., Baer A.B. Immediate hypersensitivity reaction associated with the rapid infusion of Crotalidae polyvalent immune Fab (ovine). Ann. Emerg. Med. 2002, 39:677-679.
69. Hubsy S., Host A., Teisner B., Svehag S.E. Infants and children with cow's milk allergy/intolerance. Investigation of the intake of cow's milk protein and activation of the complement system. Allergy 1990, 45:547-551.
70. Hughes N.C., Gardner B. Red cell agglutination: the first description by Creite (1869), and further observations made by Landois (1875) and Landsteiner (1901). Br. J. Haematol. 2002, 119:889-893.
71. Hui F.W., Marcopito L.F., Cardoso J.L.C., França F.O.S., Malaque C.M.S., Ferrari R.A., Theakston R.D.G., Warrell D.A. Sequential randomized and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for Bothrops snake bites. BMJ 1999, 318:1451-1453.
72. Hunter W.M., Budd P.S. Circulating antibodies to ovine and bovine immunoglobulin in healthy subjects: a hazard for immunoassays. Lancet 1980, ii:1136.
73. Isbister G.K., Brown S.G., MacDonald E., White J., Currie B.J. Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis. MJA 2008, 188:473-476.
74. Isbister G.K., Shahmy S., Mohamed F., Abeysinghe Ch., Karunathilake H., Ariaratnam A. A randomized controlled trial of two infusion rates to decrease reactions to antivenom. PLoS One 2012, 7:e38739.
75. Jancar S., Sánchez M. Immune complex-mediated tissue injury: a multistep paradigm. Trends Immunol. 2005, 26:48-55.
76. Johansson S.G.O., Bieber T., Dahl R., Friedman P.S., Lanier B.Q., Lockey R.F., Motala C., Ortega J.A., Platts-Mills T.A.E., Ring J., Thien F., Cauwenberge P.V., Williams H.C. Revised nomenclature for allergy for global use: report of the nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 2004, 113:832-836.
77. 2 fragments in high yield from serum. J. Immunol. Methods 2002, 263:57-74.
78. Jones R.G.A., Landon J. A protocol for 'enhanced pepsin digestion': a step by step method for obtaining pure antibody fragments in high yield from serum. J. Immunol. Methods 2003, 275:239-250.
79. Jorge M.T., Cardoso J.L., Castro S.C.B., Ribeiro L., França F.O.S., de Almeida M.E.S., Kamiguti A.S., Santo-Martins I.S., Santero M.L., Mancau J.E.C., Warrell D.A., Theakston R.D.G. A randomized 'blinded' comparison of two doses of antivenom in the treatment of Bothrops envenoming in São Paulo, Brazil. Trans. R. Soc. Trop. Med. Hyg. 1995, 89:111-114.
80. Karlson-Stiber C., Persson H., Heath A., Smith D., Al-Abdulla I.H., Sjöström L. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. J. Intern. Med. 1997, 241:53-58.
81. Kasturiratne A., Wickremasinghe R., de Silva N., Gunawardena K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D., de Silva J. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008, 5:e218.
82. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun. Rev. 2012, 11:792-794.
83. Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol. Immunol. 2001, 38:175-187.
84. Koskinen S., Hirvonen M., Tolo H. An enzyme immunoassay for the determination of anti-IgA antibodies using polyclonal human IgA. J. Immunol. Methods 1995, 179:51-58.
85. Kricka L.J. Human anti-animal antibody interferences in immunological assays. Clin. Chem. 1999, 45:942-956.
86. Kroez M., Kanzy E.J., Gronski P., Dickneite G. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 2003, 31:277-286.
87. Kurimoto T., Ikeda A., Tanaka K. Purification and identification of horse serum IgA. J. Vet. Sci. 1982, 44:661-668.
88. Lacroix-Desmazes S., Mouthon L., Coutinho A., Kazatchkine M.D. Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self-antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Eur. J. Immunol. 1995, 25:2598-2604.
89. Laing G.D., Lee L., Smith D.C., Landon J., Theakston R.G.D. Experimental assessment of a new low-cost antivenom for treatment of carpet viper (Echis ocellatus) envenoming. Toxicon 1995, 33:307-313.
90. Lalloo D.G., Theakston R.D. Snake antivenoms. J. Toxicol. Clin. Toxicol. 2003, 41. 277-290; 317-327.
91. Landon J., Smith D.C. Development of novel antivenoms based on specific ovine Fab. Envenomings and Their Treatments 1996, 173-180. Editions Fondation Marcel Mérieux, Lyon. C. Bon, M. Goyffon (Eds.).
92. Landon J., Smith D.C. Merits of sheep antisera for antivenom manufacture. J. Toxicol. 2003, 22:15-22.
93. Lavonas E.J., Benson B.E., Seifert S.A. Failure to develop sensitization despite repeated administration of ovine Fab snake antivenom: update of a single-patient, multicenter case series. Ann. Emerg. Med. 2013, 61:371-372.
94. 2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions. Toxicon 2001, 39:793-801.
95. León G., Lomonte B., Gutiérrez J.M. Anticomplementary activity of equine whole IgG antivenoms: comparison of three fractionation protocols. Toxicon 2005, 45:123-128.
96. León G., Rodríguez M., Rucavado A., Fernandez I., Lomonte B., Gutiérrez J.M. Anti-human erythrocyte antibodies in horse-derived antivenoms used in the treatment of snakebite envenomations. Biologicals 2007, 35:5-11.
97. León G., Segura A., Herrera M., Otero R., França F.O.S., Barbaro K.C., Cardoso J.L.C., Wen F.H., Medeiros C.R., Lopes J.C., Malaque C.M., Lomonte B., Gutiérrez J.M. Human heterophilic antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:1115-1119.
98. Lerino F.L., Powell M.S., McKenzie I.F., Hogarth P.M. Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction. J. Exp. Med. 1993, 178:1617-1628.
99. Levinson S.S., Miller J.J. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin. Chim. Acta 2002, 325:1-15.
100. LoVecchio F., Klemens J., Roundy E.B., Klemens A. Serum sickness following administration of antivenin (Crotalidae) polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ. Med. 2003, 14:220-221.
101. Magalhães P.O., Lopes A.M., Mazzola P.G., Rangel-Yagui C., Penna T.C.V., Pessoa A. Methods of endotoxins removal from biological preparations: a review. J. Pharm. Pharmaceut. Sci. 2007, 10:388-404.
102. Malasit P., Warrell D.A., Chanthavanich P., Viravan C., Mongkolsapaya J., Singhthong B., Supich C. Prediction, prevention and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. BMJ 1986, 292:17-20.
103. Maya C., Vasantha M., Krishnan L.K. Development of viper-venom antibodies in chicken egg yolk and assay of their antigen binding capacity. Toxicon 2002, 40:857-861.
104. Meenatchisundaram S., Parameswari G., Michael A., Ramalingam S. Neutralization of the pharmacological effects of Cobra and Krait venoms by chicken egg yolk antibodies. Toxicon 2008, 52:221-227.
105. Meyer W.P., Habib A.G., Onoyode A.A., Yakabu A., Smith D.C., Nosidi A., Dadu I.J., Warrell D.A., Theakston R.D.G. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur serum (IPSER) Africa antivenom. Am. J. Trop. Med. Hyg. 1997, 56:291-300.
106. Mhatre R., Nashabeh W., Schmalzing D., Yao X., Fuchs M., Whitney D., Regnier F. Purification of antibody Fab fragments by cation-exchange chromatography and pH gradient elution. J. Chromatogr. A 1995, 707:225-231.
107. 2 fragments. Toxicon 1994, 32:725-734.
108. Morais V., Massaldi H. Effect of pepsin digestion on the antivenom activity of equine immunoglobulins. Toxicon 2005, 46:876-882.
109. Morais V.M., Massaldi H. Snake antivenoms: adverse reactions and production technology. J. Venom. Anim. Toxins Incl. Trop. Dis. 2009, 15:2-18.
110. Morais V., Berasain P., Ifrán S., Carreira S., Tortorella M.N., Negrín A., Massaldi H. Humoral immune responses to venom and antivenom of patients bitten by Bothrops snakes. Toxicon 2012, 59:315-319.
111. Moran N.F., Newman W.J., Theakston R.D.G., Warrell D.A., Wilkinson D. High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:69-70.
112. Morgan A.C., Rossen R.D., Twomey J.J. Naturally occurring circulating immune complexes: normal human serum contains idiotype-anti-idiotype complexes dissociable by certain IgG antiglobulins. J. Immunol. 1979, 122:1672-1680.
113. Nakamura H., Katsura T. Immunochemical studies on diphtheria antitoxin. VI. Comparative studies of horse T and antitoxins in the quantitative precipitin reaction, complement-fixation and indirect hemagglutination of tanned and toxin coated erythrocytes. Jpn. J. Exp. Med. 1964, 34:167-196.
114. Nelson J.L., Nardella F.A., Mannik M. Competition between antigen and anti-idiotypes for rheumatoid factors. J. Immunol. 1985, 135:2357-2361.
115. Nielsen H., Sorensen H., Faber V., Svehag S.E. Circulating immune complex, complement activation kinetics and serum sickness following treatment with heterologous anti-snake venom globulin. Scand. J. Immunol. 1978, 7:25-33.
116. Ogoina D. Fever, fever patterns and diseases called "fever" - a review. J. Infect. Public Health 2011, 4:108-124.
117. Ott D., Murgott J., Rafalzik S., Wuchert F., Schmalenbeck B., Roth J., Gerstberger R. Neurons and glial cells of the rat organum vasculosum laminated terminalis directly respond to lipopolysaccharide and pyrogenic cytokines. Brain Res. 2010, 1363:93-106.
118. Otero R., Gutiérrez J.M., Rojas G., Nuñez V., Díaz A., Miranda E., Uribe A.F., Silva J.F., Ospina J.G., Medina Y., Toro M.F., García M.E., León G., García M., Lizano S., De La Torre J., Márquez J., Mena Y., González N., Arenas L.C., Puzón A., Blanco N., Sierra A., Espinal M.E., Arboleda M., Jiménez J.C., Ramírez P., Díaz M., Guzmán M.C., Barros J., Henao S., Ramírez A., Macea U., Lozano R. A randomized blind clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops snake bites in Colombia. Correlation between safety and biochemical characteristics of antivenoms. Toxicon 1999, 37:895-908.
119. Otero R., León G., Gutiérrez J.M., Rojas G., Toro M.F., Barona J., Rodríguez V., Díaz A., Núñez V., Quintana J.C., Ayala Sh., Mosquera D., Conrado L.L., Fernández D., Arroyo Y., Paniagua C.A., López M., Ospina C.E., Alzate C., Fernández J., Meza J.J., Silva J.F., Ramírez P., Fabra P.E., Ramírez E., Córdoba E., Arrieta A.B., Warrell D., Theakston D. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without β-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:1173-1182.
120. Otero-Patiño R., Cardoso J.L.C., Higashi H.G., Nuñez V., Díaz A., Toro M.F., García M.E., Sierra A., García L.F., Moreno A.M., Castañeda N., Silva-Díaz J.F., Murcia M., Cardenas S.Y., Dias da Silva W., The Regional Group on Antivenom Therapy Research (REGATHER) A randomized blinded comparative trial of one pepsin-digested and two whole IgG antivenoms in Bothrops snake bites in Urabá, Colombia. Am. J. Trop. Med. Hyg. 1998, 58:183-189.
121. ®. Un antiveneno polivalente producido en México. IATREIA 2007, 20:244-262.
122. 2 antivenoms, in Bothrops asper bites in Colombia. Toxicon 2012, 59:344-355.
123. Paganelli R., Levinsky R.J., Brostoff J., Wraith D.G. Immune complexes containing food proteins in normal and atopic subjects after oral challenge and effect of sodium cromoglycate on antigen absorption. Lancet 1979, i:1270-1272.
124. Paganelli R., Levinsky R.J., Atherton D.J. Detection of specific antigen within circulating immune complex: validation of the assay and its application in food antigen-antibody complex formed in healthy and food allergic subjects. Clin. Exp. Immunol. 1981, 46:44-53.
125. Pardal P., Souza S., Monteiro M.R., Fan H., Cardoso J.L., França F.O., Tomy S., Sano-Martins I., de Sousa M.C., Colombini M., Kodera N.F., Moura-da-Silva A.M., Cardoso D., Velarde D., Kamiguti A., Theakston R.D.G., Warrell D.A. Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans. R. Soc. Trop. Med. Hyg. 2004, 98:28-42.
126. Parfentjev, I.A., 1936. Method for purification of anti-toxins and the like. U.S. Patent 2,065,196.
127. Peri F., Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR$) antagonists. Biotechnol. Adv. 2012, 30:251-260.
128. Phisalix C., Bertrand G. Sur la propriété antitoxique du sang des animaux vaccinés contre le venin de vipère. Comptes Rendus Soc. Biol. 1894, 46:111-113.
129. Pope C.G. The action of proteolytic enzymes on the antitoxins and proteins in immune sera. I. True digestion of the proteins. Br. J. Exp. Pathol. 1939, 20:132-149.
130. Porter R.R. The hydrolysis of rabbit γ globulin and antibodies with crystalline papain. Biochemical 1959, 73:119-126.
131. Premawardhena A.P., De Silva C.E., Fonseka M.M.D., Gunatilake S.B., da Silva H.J. Low dose subcutaneous adrenalin to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomized, placebo controlled trial. BMJ 1999, 318:1041-1043.
132. Prince A.M.D., Brotman B., Ikram H. Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet 1973, i:1346-1350.
133. Rajan T.V. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol. 2003, 24:376-379.
134. Raw I., Guidolin R., Higashi H., Kelen E. Antivenins in Brazil: preparation. Reptile Venoms and Toxins 1991, 557-581. Marcel Dekker, Nueva York. A.T. Tu (Ed.).
135. Raweerith R., Ratanabanangkoon K. Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography. J. Immunol. Methods 2003, 282:63-72.
136. Redwan el-R.M., Fahmy A., El Hanafy A., Abd El-Baky N., Sallam S.M. Ovine anti-rabies antibody production and evaluation. Comp. Immunol. Microbiol. Infect. Dis. 2009, 32:9-19.
137. Restani P., Fiocchi A., Beretta B., Velona B., Giovannini M., Galli C.L. Meat allergy. III. Proteins involved and cross-reactivity between different animal species. J. Am. Coll. Nutr. 1997, 16:383-389.
138. Riviére G., Choumet V., Audebert F., Saboraund A., Debray M., Scherrman J.M., Bon C. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J. Pharmacol. Exp. Ther. 1997, 281:1-8.
139. Rojas G., Jiménez J.M., Gutiérrez J.M. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 1994, 32:351-363.
140. Roux K.H., Tankersley D.L. A view of the human idiotypic repertoire. Electron microscopic and immunologic analysis of spontaneous idiotype- anti-idiotype dimers in pooled human IgG. J. Immunol. 1990, 144:1387-1395.
141. Russell F.E., Timmerman W.F., Meadows P.E. Clinical use of antivenin prepared from goat serum. Toxicon 1970, 8:63-65.
142. Sampson H.A. Role of immediate hypersensitivity in the pathogenesis of atopic dermatitis. Allergy 1989, 44:52-58.
143. Sandler G., Eckrich R., Malamut D., Mallory D. Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions. Blood 1994, 84:2031-2035.
144. Schaeffer T.H., Khatri V., Reifler L.M., Lavonas E.J. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crolatidae polyvalent immune Fab antivenom: a meta-analysis. Acad. Emerg. Med. 2012, 19:121-131.
145. Segura A., Herrera M., Villalta M., Vargas M., Gutiérrez J.M., León G. Assessment of snake antivenom purity by comparing physicochemical and immunochemical methods. Biologicals 2013, 41:93-97.
146. Sehrawat S., Singh A. Anti-erythrocyte natural antibody activity in the unconventional 'heavy chain' immunoglobulins of Indian desert camel (Camelus dromedarius). Vet. Immunol. Immunopathol. 2006, 111:139-147.
147. Sevcik C., Díaz P., D'Suze G. On the presence of antibodies against bovine, equine and poultry immunoglobulins in human IgG preparations, and its implications on antivenom production. Toxicon 2008, 51:10-16.
148. Simpson I.D. A study of the current knowledge base in treating snake bite amongst doctors in the high-risk countries of India and Pakistan: does snake bite treatment training reflect local requirements?. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:1108-1114.
149. 2. Biologicals 2012, 40:338-344.
150. Sjostrom L., Al-abdulla I.H., Rawat S., Smith D.C., Landon J. A comparison of ovine and equine antivenoms. Toxicon 1994, 32:427-433.
151. Skarnes R.C., Brown S.K., Hull S.S., McCracken J.A. Role of prostaglandin E in the biphasic fever response to endotoxin. J. Exp. Med. 1981, 154:1212-1224.
152. Smith D.C., Reddi K.R., Laing G., Theakston R.D.G., Landon J. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 1992, 30:865-871.
153. Spitzauer S., Schweiger Ch., Wolfgang R., Pandjaitana B., Valent P., Mühla S., Ebner Ch., Scheiner O., Kraft D., Rumpold H., Valenta R. Molecular characterization of dog albumin as a cross-reactive allergen. J. Allergy Clin. Immunol. 1994, 93:614-627.
154. Spitzauer S., Pandjaitan B., Söregi G., Mühl S., Ebner C., Kraft D., Valenta R., Rumpold H. IgE cross reactivities against albumins in patients allergic to animals. J. Allergy Clin. Immunol. 1995, 96:951-959.
155. Stead S.L., Caldow M., Sharma A., Ashwin H.M., Sharman M., de-Rijk A., Stark J. New method for the rapid identification of tetracycline residues in foods or animal origin using the PremiTest in combination with a metal ion chelation assay. Food Addit. Contam. 2007, 24. 583-583.
156. Stephan W. Undergraded human immunoglobulin for intravenous use. Vox Sang. 1975, 28:422-437.
157. Stone S.F., Isbister G.K., Shahmy S., Mohamed F., Abeysinghe C., Karunathilake H., Ariaratnam A., Jacoby-Alner T.E., Cotterell C.L., Brown S.G. Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation. PLoS Negl. Trop. Dis. 2013, 7(7):e2326. 25.
158. Sutherland S.K. Serum reactions. An analysis of commercial antivenoms and the possible role of anticomplementary activity in de-novo reactions to antivenoms and antitoxins. Med. J. Aust. 1977, 1:613-615.
159. Sutherland S.K. Antivenom use in Australia. Premedication, adverse reaction and the use of venom detection kits. Med. J. Aust. 1992, 157:734-739.
160. Sutherland S.K., Lovering K.E. Antivenoms: use and adverse reactions over a 12-month period in Australia and Papua New Guinea. Med. J. Aust. 1979, 2:671-674.
161. Szalai A.J., Digerness S.B., Agrawal A., Kearney J.F., Bucy R.P., Niwas S., Kilpatrick J.M., Babu Y.S., Volanakis J.E. The Arthus reaction in rodents: species-specific requirement of complement. J. Immunol. 2000, 164:463-468.
162. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-121.
163. Taranta A., Franklin E.C. Complement fixation by antibody fragments. Science 1961, 134:1981-1982.
164. Taub A.M. Antivenins available for the treatment of snake bite. Toxicon 1964, 2:71-77.
165. Theakston R.D.G., Warrell D.A. Antivenoms: a list of hyperimmune sera currently available for the treatment of envenoming by bites and stings. Toxicon 1991, 29:1419-1470.
166. Theakston R.D.G., Fan H.W., Warrell D.A., da Silva W.D., Ward S.A., Higashi H.G., BIASG Use of enzyme immunoassays to compare the effects and assess the dosage regimens of three Brazilian Bothrops antivenoms. Am. J. Trop. Med. Hyg. 1992, 47:593-604.
167. 2 antivenom for snakebites in Thailand. Acta Trop. 2008, 105:203-205.
168. 2 antivenom serum for Bothrops lanceolatus bites in Martinique. Lancet 1996, 347:406.
169. Vaerman J.P., Querinjean J.F., Heremans J.F. Studies on the IgA system of the horse. Immunology 1971, 21:443-454.
170. Vargas M., Segura A., Herrera M., Villalta M., Estrada R., Cerdas M., Winkel K.D., León G., Williams D., Gutiérrez J.M. Preclinical evaluation of a caprylic acid fractionated whole IgG antivenom for the treatment of envenomings by Oxyuranus scutellatus canni in Papua New Guinea. PLoS Negl. Trop. Dis. 2011, 5(5):e1144.
171. Vyas G.N., Perkins H.A., Fudenberg H.H. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet 1968, ii:312-315.
172. Vyas G.N., Holmdahl L., Perkins H.A., Fudenberg H.H. Serologic specificity of human anti-IgA and its significance in transfusion. Blood 1969, 34:573-581.
173. Vyas G.N., Perkins H.A., Yang Y.M., Basantani G.K. Healthy blood donors with selective absence of immunoglobulin A: prevention of anaphylactic transfusion reactions caused by antibodies to IgA. J. Lab. Clin. Med. 1975, 85:838-842.
174. Wagner B., Miller D.C., Lear T.L., Antczak D.F. The complete map of the Ig heavy chain constant gene region reveals evidence for seven IgG isotypes and for IgD in the horse. J. Immunol. 2004, 173:3230-3242.
175. Waldesbuhl M., Allan R., Meylan A., Isliker H. Anticomplementary activity of gamma G-immunoglobulins and of their subunits. Immunochemistry 1970, 7:185-197.
176. Warrell D.A., Davidson N.M., Omerod L.D., Pope H.M., Watkins B.J., Greenwood B.M., Ried H.A. Bites by the saw-scaled or carpet viper (Echis carinatus): trial of two specific antivenoms. Br. Med. J. 1974, 4(5942):437-440.
177. Werfel S.J., Cooke S.K., Sampson H.A. Clinical reactivity to beef in children allergic to cow's milk. J. Allergy Clin. Immunol. 1997, 99:293-300.
178. Williams D.J., Jensen S.D., Nimorakiotakis B., Müller R., Winkel K.D. Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea. Toxicon 2007, 49:780-792.
179. Williams D., Gutiérrez J.M., Harrison R., Warrell D.A., White J., Winkel K.D., Gopalakrishnakone P., Global Snake Bite Initiative Working Group, International Society on Toxinology The Global Snake Bite Initiative: an antidote for snake bite. Lancet 2010, 375:89-91.
180. Willman J.H., Martins T.B., Jaskowski T.D., Hill H.R., Litwin Ch.M. Heterophile antibodies to bovine and caprine proteins causing false-positive human immunodeficiency virus type 1 and other enzyme-lined immunosorbent assay results. Clin. Diagn. Lab. Immunol. 1999, 6:615-616.
181. World Health Organization Progress in the Characterization of Venoms and Standarization of Antivenoms 1981, WHO Offset Publication, Geneva.
182. World Health Organization Guidelines for the Production, Control and Regulation of Snake Antivenoms Immunoglobulins 2010, World Health Organization, Geneva. http://www.who.int/bloodproducts/snakeantivenoms.
183. World Health Organization Guidelines for the Prevention and Clinical Management of Snakebite in Africa 2010, World Health Organization Regional Office for Africa, Brazzaville. http://apps.who.int/medicinedocs/documents/s17810en/s17810%20en.pdf.
184. Yong-Cheng L., Wen-Chen Y., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.